Phase III iptacopan versus placebo in acetylcholine receptor-positive generalized myasthenia gravis

Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing Iptacopan + stable standard of care, Placebo + stable standard of care and Open-label extension iptacopan (3 arms). Primary endpoint: Change from baseline to Month 6 in Myasthenia Gravis Activity of Daily Living total score. Started Jul 2024; status: completed.